Evidence map›Paper›PMID 41924922›Full record

ArticleHaematologica2026

First-year results of the International Leukemia/ Lymphoma Target Board for pediatric relapsed and refractory hematological malignancies.

Uri Ilan, Judith M Boer, Maaike Luesink, Francisco Bautista, Mattias Hofmans, Aditi Vedi, Bálint Egyed, Birgit Geoerger, Ruta Tuckuviene, Bodil Als-Nielsen and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Uri IlanPrincess Máxima Center for Pediatric Oncology, Utrecht.
Judith M BoerPrincess Máxima Center for Pediatric Oncology, Utrecht.
Maaike LuesinkPrincess Máxima Center for Pediatric Oncology, Utrecht.
Francisco BautistaPrincess Máxima Center for Pediatric Oncology, Utrecht.
Mattias HofmansDepartment of Laboratory Medicine, Ghent University Hospital, Ghent.
Aditi VediCambridge University Hospitals NHS Foundation Trust, Cambridge.
Bálint EgyedDepartment of Pediatrics, Semmelweis University, Budapest.
Birgit GeoergerGustave Roussy Cancer Center, Department of Pediatric and Adolescent Oncology, INSERM U1015, Université Paris-Saclay, Villejuif.
Ruta TuckuvieneDepartment of Pediatrics, Aalborg University Hospital, Aalborg.
Bodil Als-NielsenDepartment of Pediatrics and Adolescent Medicine, University Hospital Rigshospitalet, Copenhagen.
Pablo VelascoPediatric Oncology and Hematology Department, Hospital Vall d'Hebrón, Barcelona.
Jose Luis FusterSección de Oncohematología Pediátrica, Hospital Virgen de Arrixaca, Murcia.
Alba RubioPediatric Oncology and Hematology Department, Hospital Infantil Universitario Niño Jesús, Madrid.
Sarah K TasianPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands; Children's Hospital of Philadelphia, Division of Oncology and Center for Childhood Cancer Research; Philadelphia, Pennsylvania, USA; University of Pennsylvania School of Medicine, Department of Pediatrics; Philadelphia, Pennsylvania.
Frederik van DelftWolfson Childhood Cancer Research Centre, Newcastle University Centre for Cancer, Newcastle upon Tyne.
Julie A E IrvingNorthern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne.
Dániel J ErdélyDepartment of Pediatrics, Semmelweis University, Budapest.
Kjeld SchmiegelowDepartment of Pediatrics and Adolescent Medicine, University Hospital Rigshospitalet, Copenhagen.
Barbara De MoerlooseDepartment of Pediatric Hematology-Oncology and Stem Cell Transplantation, Ghent University Hospital, Ghent.
André BaruchelUniversity Hospital Robert Debré (APHP) and Université de Paris, Paris.
Monique L Den BoerPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands; Center for Translational Immunology, University Medical Center Utrecht, Utrecht. m.l.denboer@prinsesmaximacentrum.nl.
Michel C ZwaanPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands; Department of Pediatric Oncology, Erasmus MC-Sophia Children's Hospital, Rotterdam. c.m.zwaan-2@prinsesmaximacentrum.nl.

Funding

Multispecific targeting incorporating cytokine receptor pathways in high risk pediatric acute leukemias to improve durability of adoptive cell therapy-induced remissionsU01CA232486 · NCI · UNIVERSITY OF COLORADO DENVER · PI FRY, TERRY J., TASIAN, SARAH KATHLEEN · 2018 to 2018
$4.0M
Identifying Relapse Predictors and Therapeutic Vulnerabilities in Ph+ and Ph-like Acute Lymphoblastic LeukemiaR01CA293587 · NCI · SEATTLE CHILDREN'S HOSPITAL · PI LOH, MIGNON LEE-CHEUN, TASIAN, SARAH KATHLEEN · 2025 to 2025
$3.5M
Towards rational design of combination therapeutic targetsU01CA243072 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · PI TAN, KAI, TASIAN, SARAH KATHLEEN · 2020 to 2024
$2.6M
NCI NIH HHS R01 CA293587NCI NIH HHS U01 CA232486NCI NIH HHS U01 CA243072
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID41924922
PMCPMC13628014

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.